Tenaya Therapeutics announced inducement stock option grants to new employees under Nasdaq Listing Rule 5635(c)(4). The grants indicate active hiring and may lead to modest shareholder dilution while reflecting confidence in the company’s prospects. Who is involved: Tenaya Therapeutics, its board of directors, newly hired employees, Nasdaq. Likely next: The company will likely file a Form S‑8 to register the inducement shares; the options are expected to vest 25% after one year then monthly.. Tenaya Therapeutics disclosed that it has issued equity inducement awards to newly hired employees in accordance with Nasdaq Listing Rule 5635(c)(4). The grants are intended to supplement compensation packages and are exempt from shareholder approval under the rule. The move signals the company’s ongoing hiring efforts as it advances its heart‑disease therapy pipeline. Likely next events: Tenaya may file an S-8 registration statement within 30 days to cover the inducement shares The granted options are expected to vest 25% after one year, then monthly on a typical four-year schedule Sectors affected: Biotechnology Pharmaceuticals Regulatory implications: Compliance with Nasdaq Listing Rule 5635(c)(4) permits inducement grants without shareholder approval Any material change to the inducement plan must be disclosed in SEC filings Historical parallels: Geron Corporation inducement grant of 1,700,000 options on July 14, 2026 under the same Nasdaq rule
INTELLIGENCE
Social Pulse
AI estimate · not scraped